University of Catania

Real-World Study Shows Pepaxti Effective in Heavily Pretreated Multiple Myeloma Patients

a month ago

• Italian researchers report promising results for Pepaxti (melflufen) in treating triple-class refractory multiple myeloma patients, achieving a 37.5% overall response rate despite patients having received a median of 3.5 prior therapies. • The University of Catania study demonstrated disease control even in high-risk patients with aggressive features like extramedullary disease, with manageable hematologic toxicities through dose adjustments and supportive care. • These real-world findings align with the HORIZON trial results, reinforcing Pepaxti's potential benefit for patients with limited treatment options, though the FDA withdrew its U.S. approval (as Pepaxto) in February 2024.

Nasal Spray Targeting Brain Enzyme zDHHC7 Shows Promise in Alzheimer's Treatment

6 months ago

• Researchers have identified that inhibiting the enzyme S-acyltransferase (zDHHC7) with a nasal spray could slow Alzheimer's progression and reduce harmful protein accumulation. • The study found elevated levels of zDHHC7 in early-stage Alzheimer's patients, which exacerbates beta-amyloid accumulation and contributes to neuronal damage. • Experiments in mice showed that inhibiting zDHHC enzymes via nasal spray reduced beta-amyloid accumulation, slowed neurodegeneration, and extended lifespan. • Funded by an €890,000 grant, the team is developing novel therapies like genetic patches and engineered proteins to selectively target zDHHC7 for human use.